StocksPODD

PODD

Insulet CorporationHealthcare / Medical DevicesINTACT

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.

Share Price
$132.31
52W: $126.4 - $354.88
DCF Fair Value
$66.94
-97.7% Premium
P/E (TTM)
24.8x
ROIC
12.1%
Operating Margin
16.2%
FCF Yield
2.6%
Debt / Equity
0.67x
Piotroski Score
8/9
Altman Z-Score
3.53
Market Cap
$9.2B

Price vs. Intrinsic Value Corridor

Overvalued vs DCF ($66.94)

Historical market price overlaid against conservative DCF Fair Value & Benjamin Graham Margin of Safety bands.

Period Return (1Y)
()
Period Range
$ - $
DCF Fair Value
$66.94
MOS Buy Target (-25%)
$50.21
Valuation Overlays:

2-Stage Discounted Cash Flow (DCF) Workbench

Conservative intrinsic value model based on owner cash generation over a 10-year investment horizon. Opens with LocalAlpha's baseline assumptions (matching the fair value shown above) — adjust any input to stress-test.

Current Market Price
$132.31
DCF Fair Value
$67.59
-95.8% Premium
$237M
$100M$237M (Reported)$50,000M
8.1%
-5%10% (Target)35%
4.5%
0%5%20%
9.0%
6%9% (Standard)15% (High Risk)
2.5%
1% (GDP Floor)2.5% (Inflation)4.0%
$400M
-$100B CashBalance Sheet+$150B Debt
10-Yr PV of Cash Flows
$2.2B
PV of Terminal Value
$2.9B
Implied Enterprise Value
$5.1B
Implied Equity Value
$4.7B
YearYr 1Yr 2Yr 3Yr 4Yr 5Yr 6Yr 7Yr 8Yr 9Yr 10
Projected FCF ($M)$256$277$299$324$350$366$382$399$417$436
Present Value (PV)$235$233$231$229$227$218$209$200$192$184

Benjamin Graham & Buffett Value Models

Classical deep value metrics based on asset backing, normalized earnings power, and owner cash yield.

Graham Number-166.8% Premium
$49.59

Calculated as √(22.5 × EPS × BVPS). The maximum theoretical price a defensive investor should pay based purely on asset book value and current earnings.

EPS: $5.33BVPS: $20.51
Revised Graham Formula-31.5% Premium
$100.65

Formula: V = (EPS × (8.5 + 2g) × 4.4) / Y where g is the conservative 7-10 yr growth rate and Y is AAA Bond Yield.

Buffett Owner Earnings2.5% Yield
$3.26 / share

True distributable cash flow: Net Income + D&A - Maintenance CapEx. Reflects the cash Buffett would extract without hurting unit volume.

Total: $0.2BYield: 2.5%

Reverse DCF: Market Growth Expectation

HIGH BARRIER
14.3% CAGR (Next 10 Yrs)

At the current price of $132.31, the market is assuming the business will compound Free Cash Flow at 14.3% per year for the next decade with a 9% hurdle rate.

Value Investor Verdict
ℹ Fair expectations: Requires steady execution.
Autonomous Thesis Underwriting

Surveil PODD with Mathematical Margin of Safety Rules

Set non-negotiable floor rules for Insulet Corporation. If a newly filed quarterly 10-Q breaks your ROIC floor, operating margin boundary, or balance sheet leverage rules, receive an autonomous breach audit within 15 minutes.

Buffett Quality

ROIC > 15% • Margin > 15% • D/E < 0.5x

Margin Floor Guard

Current Margin 16.2% • Floor > 10%

Solvency Guard

Altman-Z > 2.6 • Current Ratio > 1.5x

Frequently Asked Questions: Insulet Corporation (PODD) Intrinsic Valuation

Audited fundamentals, DCF intrinsic value sensitivity, and thesis break detection parameters for Insulet Corporation.

Based on institutional multi-stage Discounted Cash Flow (DCF) modeling on audited SEC cash flows, Insulet Corporation has an estimated DCF intrinsic fair value of $66.94 per share compared to its current market price of $132.31. This represents an estimated 97.7% premium over fair value. Additionally, its classic Benjamin Graham Number stands at $49.59.

Related Healthcare Value Stocks & Sector Peers

Compare Insulet Corporation with audited intrinsic valuation models across the Healthcare sector.

View All S&P 500 Stocks